The initial public offering (IPO) of Windlas Biotech, a pharmaceutical formulations contract development and manufacturing organisation, will open for public subscription on August 4.
Along with this, Devyani International, Krsnaa Diagnostics and Exxaro Tiles will also be launching their IPO on the same day.
Here are key details about Windlas Biotech IPO:
About Windlas Biotech
Windlas Biotech Ltd is amongst the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (CDMO) industry in India in terms of revenue.
It operates under three distinct strategic business verticals CDMO Services and Products; Domestic Trade Generics and over-the-counter (OTC) Brands; and Exports.
In FY20, the company’s market share was around 1.5 percent in terms of revenue in the domestic formulations CDMO industry.
The company has developed relationships with various leading pharmaceutical companies including Pfizer Ltd, Sanofi India Ltd, Zydus Cadila Healthcare Ltd, Emcure Pharmaceuticals Ltd, Eris Lifesciences Ltd, Intas Pharmaceuticals Ltd and Systopic Laboratories Pvt Ltd.
In FY20, Windlas Biotech provided CDMO services to 7 out of the top 10 Indian formulations pharmaceutical companies.
Windlas currently owns and operate 4 manufacturing facilities located at Dehradun in Uttarakhand. As of March 31, 2021, their manufacturing facilities had an aggregate installed operating capacity of 7,063.83 million tablets/ capsules, 54.46 million pouch/sachets and 61.08 million liquid bottles.
The company’s revenue from operations in FY21 was at Rs 427.60 crore, registering a growth of 30.03 percent from Rs 328.85 crore in FY20. Revenue in FY19 was at Rs 307.27 crore. Net Profit in FY21, FY20 and FY19 was at Rs 15.57 crore, Rs 16.21 crore and Rs 63.82 crore, respectively.
Promoters & Management
Vivek Dhariwal is the Chairman and Non-Executive Independent Director and Ashok Kumar Windlass is the Wholetime Director of the company.
Hitesh Windlass is the Promoter and Managing Director and Manoj Kumar Windlass is the Promoter and Joint Managing Director of the company.
Pawan Kumar Sharma is the Executive Director of the company, while Prachi Jain Windlass is the Non-Executive Director of the company.
Srinivasan Venkataraman and Gaurav Gulati are the Non-Executive Independent Directors of the company.
Komal Gupta is the CFO and Shailesh Gokhale is the Chief Operating Officer.
Allotment & Listing
The company is expected to finalise the IPO share allotment on August 11 and the refunds or unblocking ASBA fund would be initiated on August 12.
The trading of Windlas Biotech shares is likely to commence on August 17 on NSE and BSE.
First Published: IST